{"id":"coronavac-bnt162b2","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or swelling"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CoronaVac is an inactivated whole-virus vaccine that primes the immune system with killed SARS-CoV-2 particles. BNT162b2 is an mRNA vaccine encoding the spike protein that provides a booster response. The heterologous prime-boost strategy aims to generate robust cellular and humoral immunity against multiple viral epitopes.","oneSentence":"This is a combination COVID-19 vaccine regimen using CoronaVac (inactivated virus vaccine) followed by BNT162b2 (mRNA vaccine) to stimulate immune responses against SARS-CoV-2.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:07:44.114Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention (heterologous prime-boost regimen)"}]},"trialDetails":[{"nctId":"NCT07408297","phase":"PHASE2","title":"Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda","status":"COMPLETED","sponsor":"Victoria Biomedical Research Institute","startDate":"2022-05-18","conditions":"COVID -19, SARS CoV 2 Infection","enrollment":1919},{"nctId":"NCT05599555","phase":"","title":"Community-based Sero-epidemiological Study of COVID-19","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2022-04-28","conditions":"COVID-19","enrollment":9600},{"nctId":"NCT05697705","phase":"","title":"Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-07-22","conditions":"COVID-19","enrollment":188814085},{"nctId":"NCT05501522","phase":"PHASE3","title":"Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older","status":"COMPLETED","sponsor":"SK Bioscience Co., Ltd.","startDate":"2022-12-09","conditions":"COVID-19","enrollment":840},{"nctId":"NCT06597370","phase":"","title":"Immunogenicity Induced by COVID-19 Vaccines in Mexican Population","status":"COMPLETED","sponsor":"National Polytechnic Institute, Mexico","startDate":"2021-09-01","conditions":"COVID-19 Vaccine","enrollment":80},{"nctId":"NCT05387317","phase":"PHASE3","title":"Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia)","status":"WITHDRAWN","sponsor":"Murdoch Childrens Research Institute","startDate":"2024-04","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04898946","phase":"","title":"Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong","status":"COMPLETED","sponsor":"Hong Kong Sanatorium & Hospital","startDate":"2021-03-07","conditions":"Covid-19 Vaccine","enrollment":480},{"nctId":"NCT04832932","phase":"","title":"The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes","status":"UNKNOWN","sponsor":"Mebo Research, Inc.","startDate":"2021-01-05","conditions":"COVID-19 Vaccines","enrollment":2000},{"nctId":"NCT04800133","phase":"PHASE2","title":"Covid-19 Vaccination in Adolescents and Children","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2021-05-08","conditions":"Covid19","enrollment":1018},{"nctId":"NCT05057169","phase":"PHASE4","title":"Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study)","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2021-11-18","conditions":"COVID-19 Vaccination","enrollment":400},{"nctId":"NCT05052307","phase":"","title":"A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine in Brazil","status":"COMPLETED","sponsor":"Hospital Moinhos de Vento","startDate":"2021-11-03","conditions":"Covid19","enrollment":4574},{"nctId":"NCT05403307","phase":"","title":"A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine Among Children in Brazil","status":"COMPLETED","sponsor":"Hospital Moinhos de Vento","startDate":"2022-06-08","conditions":"COVID-19","enrollment":757},{"nctId":"NCT05788185","phase":"PHASE1, PHASE2","title":"Safety & Immunogenicity of RVM-V001/RVM-V002 or RVMV001+RVMV002 (Co Administered as Separate Injections) in Healthy Individuals","status":"TERMINATED","sponsor":"RVAC Medicines (US), Inc.","startDate":"2023-03-22","conditions":"Infectious Disease, COVID-19","enrollment":24},{"nctId":"NCT04775069","phase":"PHASE4","title":"Antibody Response to COVID-19 Vaccines in Liver Disease Patients","status":"COMPLETED","sponsor":"Humanity & Health Medical Group Limited","startDate":"2021-05-21","conditions":"Chronic Liver Disease","enrollment":232},{"nctId":"NCT05710289","phase":"","title":"A Blood Collection Study to Assess the Immunogenicity of Nationally Authorized Homologous COVID-19 Booster Vaccines Among Adult Vaccinees.","status":"WITHDRAWN","sponsor":"SK Bioscience Co., Ltd.","startDate":"2023-02","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05228912","phase":"","title":"Immunization of 7 Different Vaccines Against SARS-COV-2 Across 4 Countries.","status":"COMPLETED","sponsor":"Hospital Clinica Nova","startDate":"2021-02-26","conditions":"Vaccine Adverse Reaction, COVID-19, Vaccine Reaction","enrollment":1870},{"nctId":"NCT05668065","phase":"PHASE3","title":"Immunogenicity of Heterologous Versus Homologous Prime Boost Schedule With mRNA and Inactivated COVID-19 Vaccines","status":"COMPLETED","sponsor":"Institut Pasteur de Tunis","startDate":"2021-11-22","conditions":"COVID-19","enrollment":199},{"nctId":"NCT05029245","phase":"PHASE3","title":"IntraDermal Versus Intramuscular Comirnaty® Efficacy Study","status":"WITHDRAWN","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2021-08-31","conditions":"Covid19 Vaccine, Covid19","enrollment":""},{"nctId":"NCT04834869","phase":"","title":"COVID-19 Vaccines Safety Tracking (CoVaST)","status":"RECRUITING","sponsor":"Masaryk University","startDate":"2021-04-01","conditions":"Adverse Reaction to Vaccine, COVID19 Vaccine","enrollment":30000},{"nctId":"NCT05225285","phase":"PHASE3","title":"Efficacy, Immunogenicity and Safety of Inactivated Vaccine (Coronavac) Against SARS-COV2 in Children and Adolescents","status":"UNKNOWN","sponsor":"Federal University of Espirito Santo","startDate":"2022-01-21","conditions":"COVID-19","enrollment":1120},{"nctId":"NCT05119738","phase":"","title":"Immune Response to Third Dose of SARS-CoV-2 Vaccine in a Cohort of Cancer Patients on Active Treatment","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2021-10-27","conditions":"Sars-CoV-2 Infection","enrollment":122},{"nctId":"NCT05124509","phase":"","title":"Immune Response to Third Dose of COVID-19 Vaccine in Solid Organ Transplant","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2021-10-06","conditions":"COVID-19, SARS-CoV-2 Infection, Solid Organ Transplant","enrollment":147},{"nctId":"NCT04992182","phase":"PHASE2","title":"Reactogenicity, Safety, and Immunogenicity of Covid-19 Vaccine Booster","status":"UNKNOWN","sponsor":"Universidad del Desarrollo","startDate":"2021-07-08","conditions":"Covid19","enrollment":534}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CoronaVac/BNT162b2","genericName":"CoronaVac/BNT162b2","companyName":"Institut Pasteur de Tunis","companyId":"institut-pasteur-de-tunis","modality":"Biologic","firstApprovalDate":"","aiSummary":"This is a combination COVID-19 vaccine regimen using CoronaVac (inactivated virus vaccine) followed by BNT162b2 (mRNA vaccine) to stimulate immune responses against SARS-CoV-2. Used for COVID-19 prevention (heterologous prime-boost regimen).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}